C. difficile Toxoid Vaccine Regimen for Recurrence Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections, particularly recurrences, are inadequate, with high recurrence rates and a lack of effective non-invasive therapeutic options, highlighting the need for immunogenic and therapeutic compositions to prevent severe outcomes and recurrences.
Innovation Solution
Development of a Clostridium difficile vaccine regimen using highly purified toxoids A and B, administered in multiple doses with optimal timing and adjuvants to induce sustained neutralizing antibody responses, providing long-term protection against C. difficile infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic treatment (metronidazole and vancomycin) is used for C. difficile infection, then the infection can be treated initially, but recurrence occurs in about 20% of patients with up to 50% suffering additional recurrences
Solution Approach 1:
The patent applies preliminary action by administering a vaccine containing C. difficile toxoids before infection occurs or before recurrence can happen. The vaccine primes the immune system in advance, creating protective antibodies that prevent initial infection or block recurrence, rather than treating after infection establishes itself.
Solution Approach 2:
The patent uses an intermediary approach by introducing a vaccine composition containing purified C. difficile toxoids A and B as a mediator between the pathogen and the host immune system. This intermediary triggers protective immune responses without causing disease, bridging the gap between pathogen exposure and protective immunity.
2Reliability
If inactivated toxins are used for active immunization, then animals are protected from lethal challenge, but the composition must be highly purified to ensure safety
Solution Approach 1:
The patent applies extraction by isolating and purifying only the essential protective components (toxins A and B) from the complex C. difficile bacterium. The highly purified toxoids are extracted and formulated into a vaccine, removing unnecessary bacterial components that could cause adverse reactions while retaining immunogenicity.
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical state of the toxins through formaldehyde treatment to create toxoids. This chemical modification reduces toxicity while preserving immunogenicity, changing the toxin parameters from pathogenic to protective.
3Reliability
If passive immunization with anti-toxin antibodies is administered, then protection from lethal challenge is achieved, but it does not provide long-term immunity
Solution Approach 1:
The patent applies self-service by enabling the host's own immune system to produce protective antibodies through vaccination with C. difficile toxoids. Rather than relying on externally administered antibodies that provide temporary passive immunity, the vaccine stimulates the body's own immune system to generate sustained active immunity, allowing the host to self-produce protective antibodies long-term.
Data Source
AI summary
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.